ALNA pre-market +3.16% on 252,311,606 shares 06 Jan 2026: check catalysts
The ALNA stock opened pre-market at USD 0.075, up 3.16% on heavy volume of 252,311,606 shares on NASDAQ in the United States. That move follows an intraday range from USD 0.06 to USD 0.1459 and a previous close of USD 0.0727. Traders are watching liquidity and any clinical or corporate news that could move this micro-cap biotechnology name. We use Meyka AI-powered market analysis to link the price action to the company’s financial profile and short-term outlook.
Market snapshot and trading flow
ALNA (Allena Pharmaceuticals, Inc.) trades pre-market on NASDAQ at USD 0.075, up 3.16% versus the previous close of USD 0.0727. Today’s volume is 252,311,606 shares with an open of USD 0.0641 and a intraday high of USD 0.1459 and low of USD 0.06. The stock shows extreme intraday volatility typical for small biotechs, and the current market cap reads USD 0.00 in the feed, reflecting incomplete floats or reporting quirks. For context on macro headlines that can sway small-cap healthcare names see recent coverage from Bloomberg and Reuters.
Recent company context and catalysts
Allena Pharmaceuticals, Inc. is a US biotechnology company developing oral enzyme therapeutics, led by ALLN-346 for hyperuricemia in advanced chronic kidney disease. The company lists CEO Louis Brenner and 12 full-time employees. There are no fresh SEC filings or earnings releases in the feed today; last public earnings announcement date in the record is 2022-08-15. Given the program stage, clinical updates, enrollment news, or partnership announcements remain the primary catalysts for material moves.
Financials and valuation snapshot
ALNA’s trailing EPS is -0.638 and reported PE is negative at -0.118 (rounded). Key per-share metrics show cash per share USD 0.923 and book value per share USD 0.580. Operating cash flow per share is -1.405 and free cash flow per share is -1.426, consistent with an early-stage biotech burn profile. CurrentRatio is 2.105 and debtToEquity is 0.028, indicating short-term liquidity that is modestly supportive. Enterprise value is reported as -29,461,000.00 USD in the data feed, which often signals data gaps for thinly traded micro-caps. These figures underline high operational risk and minimal revenue exposure.
Trading profile and technicals
With average volume not reported and a one-day total volume of 252,311,606, ALNA shows episodic liquidity spikes. Day-range behavior (USD 0.06–USD 0.1459) signals rapid bid-ask swings. Price-to-book is 0.129, reflecting a deep value multiple relative to book value but not meaningful for a firm with negative earnings and no commercial revenues. Short-term traders should watch support near USD 0.06 and resistance around USD 0.1459; tight risk controls are essential given reported multi-year declines (1Y -81.39%, 3Y -96.79%).
Meyka AI grade and analyst context
Meyka AI rates ALNA with a score out of 100: Score 62.74623085761357 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects limited commercial traction but reasonable liquidity ratios and cash per share versus liabilities. These grades are informational only and are not financial advice.
Risks and strategy for most-active traders
Primary risks include continuing negative earnings (EPS -0.638), clinical trial outcomes, cash runway limits, and sparse institutional coverage. For traders seeking most-active plays, position sizing should reflect high volatility and thin float dynamics. Consider stop-loss levels and avoid carrying overnight unless you have clear visibility on catalysts. Sector activity in Healthcare and Biotechnology can amplify moves in micro-caps.
Final Thoughts
Key takeaways for ALNA stock: the pre-market price of USD 0.075 on NASDAQ with 252,311,606 shares traded shows heavy intraday interest but does not confirm a sustained trend. Financially, Allena carries negative EPS of -0.638 and negative operating cash flow per share of -1.405, offset by cash per share of USD 0.923 and a current ratio of 2.105. Meyka AI’s forecast model projects a base-case 12-week target of USD 0.120, a bull scenario of USD 0.200, and a bear scenario of USD 0.030. Versus the current price of USD 0.075, the base-case implies upside of 60.00% and the bull case implies upside of 166.67%, while the bear case implies downside of -60.00%. Forecasts are model-based projections and not guarantees. Traders should weigh clinical and corporate catalysts, sector trends in Biotechnology, and the stock’s volatile short-term trading profile before taking positions. We use Meyka AI-powered market analysis to connect price moves to company fundamentals and trading metrics.
FAQs
ALNA is trading pre-market at USD 0.075 with reported volume of 252,311,606 shares and an intraday range of USD 0.06 to USD 0.1459 on NASDAQ in the United States.
Key risks include negative EPS of -0.638, negative operating cash flow per share (-1.405), limited revenue, and dependence on clinical progress and funding to sustain operations.
Meyka AI rates ALNA 62.74623085761357 (Grade B) with a HOLD suggestion. The grade blends benchmark, sector, financial growth, metrics, forecasts, and consensus. It is informational, not investment advice.
Meyka AI’s forecast model projects a base-case target of USD 0.120, a bull target of USD 0.200, and a bear target of USD 0.030 versus the current USD 0.075; these are projections, not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
